Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
The effects of tirzepatide on body weight control have also been confirmed in non-diabetic individuals in the SURMOUNT-1 study, where treatment with tirzepatide 1015 mg was associated with an average weight loss of approximately 20% at 72 weeks, exceeding 25% in one third of the patients
Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery
On the oral obesity market, Deutsche noted it is too early to call relative preferences between injectable and oral formats, with Novo's recently launched oral semaglutide product Foundayo competing against its established injectable Wegovy
May be combined with your favorite beverage
Its typically recommended that you Wegovys manufacturer says you can use the same area of your body each week as long as you change the actual injection site
